Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E ε4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology
- Kari M Mattilaa,
- Juha O Rinneb,
- Matias Röyttäc,
- Pekka Laippalad,e,
- Timo Pietiläf,
- Hannu Kalimoc,
- Timo Koivulaa,
- Harry Freyf,g,
- Terho Lehtimäkia
- aDepartment of Clinical Chemistry, Centre for Laboratory Medicine, Tampere University Hospital, Finn-Medi 2, Third Floor, PO Box 2000, FIN-33521 Tampere, Finland, bDepartment of Neurology, University of Turku, Turku, Finland, cDepartment of Pathology, University of Turku, Turku, Finland, dResearch Unit, Tampere University Hospital, Tampere, Finland, eSchool of Public Health, Medical School, University of Tampere, Tampere, Finland, fDepartment of Neurology, Tampere University Hospital, Tampere, Finland, gDepartment of Neurology, Medical School, University of Tampere, Tampere, Finland
- Dr Mattila, klkama{at}uta.fi
- Revised 15 June 2000
- Accepted 20 June 2000
Abstract
Alzheimer's disease (AD) and Parkinson's disease (PD) are genetically heterogeneous. Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) genes may modify the risk of these disorders. We investigated whether common polymorphisms present in these genes operate as risk factors for AD and PD in Finnish subjects, independently or in concert with the apolipoprotein E ε4 allele (APOE ε4). Eighty late onset sporadic AD patients, 53 PD patients (34 of whom had concomitant AD pathology), and 67 control subjects were genotyped for the insertion (I)/deletion (D) polymorphism of DCP1 and the K variant ofBCHE. In logistic regression analysis, theDCP1 *I allele in combination withAPOE ε4 significantly increased the risk of AD (OR 30.0, 95% CI 7.3-123.7), compared to subjects carrying neither of the alleles. Similar analysis showed that the risk of AD was significantly increased in subjects carrying both theBCHE wild type (*WT/*WT) genotype and ε4 (OR 9.9, 95% CI 2.9-33.8), compared to those without thisBCHE genotype and ε4. Further, the risk of PD with AD pathology was significantly increased for carriers ofDCP1 *I and ε4 (OR 8.0, 95% CI 2.1-31.1). We thus conclude that, in Finns, interaction betweenDCP1 *I and ε4 increases the risk of AD as well as of PD with coexisting Alzheimer pathology, which underlines the importance of the DCP1 I/D polymorphism in the development of Alzheimer neuropathology, whereas the wild typeBCHE genotype in combination with ε4 had a combined effect with regard to the risk of AD.
